Salim Syed
Stock Analyst at Mizuho
(1.88)
# 2,886
Out of 4,829 analysts
78
Total ratings
35.48%
Success rate
-9.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $124.40 | +35.85% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $274.76 | +1.91% | 8 | May 7, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $6.60 | +233.33% | 5 | Nov 21, 2024 | |
| NKTX Nkarta | Maintains: Outperform | $20 → $16 | $2.02 | +692.08% | 7 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $90 → $100 | $103.82 | -3.68% | 6 | Nov 21, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $99 → $103 | $32.13 | +220.57% | 6 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $31.59 | +415.99% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $6.47 | +178.21% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $18.99 | +79.04% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $37.59 | +163.37% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $35.68 | +48.54% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.90 | +565.11% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.02 | +1,958.82% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $12.35 | +191.50% | 1 | Nov 16, 2022 |
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $124.40
Upside: +35.85%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $274.76
Upside: +1.91%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $6.60
Upside: +233.33%
Nkarta
Nov 21, 2024
Maintains: Outperform
Price Target: $20 → $16
Current: $2.02
Upside: +692.08%
Gilead Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $90 → $100
Current: $103.82
Upside: -3.68%
Cytokinetics
Nov 21, 2024
Maintains: Outperform
Price Target: $99 → $103
Current: $32.13
Upside: +220.57%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $31.59
Upside: +415.99%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $6.47
Upside: +178.21%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $18.99
Upside: +79.04%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $37.59
Upside: +163.37%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $35.68
Upside: +48.54%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.90
Upside: +565.11%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.02
Upside: +1,958.82%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $12.35
Upside: +191.50%